| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 641.596 | 3.307.612 | 14.569.228 | 45.145.560 | 56.321.693 | 68.199.248 |
| Total Income - EUR | - | - | - | - | 644.717 | 3.316.135 | 14.615.797 | 45.293.749 | 56.761.503 | 69.066.386 |
| Total Expenses - EUR | - | - | - | - | 530.334 | 3.203.352 | 14.297.218 | 44.198.559 | 54.922.875 | 66.848.809 |
| Gross Profit/Loss - EUR | - | - | - | - | 114.383 | 112.783 | 318.579 | 1.095.190 | 1.838.628 | 2.217.576 |
| Net Profit/Loss - EUR | - | - | - | - | 94.818 | 103.967 | 271.201 | 942.834 | 1.579.487 | 1.527.315 |
| Employees | - | - | - | - | 4 | 5 | 5 | 5 | 7 | 7 |
Check the financial reports for the company - Addenda Pharmaceuticals S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 4.173 | 4.046 | 4.906 | 5.449 | 5.160 | 15.727 |
| Current Assets | - | - | - | - | 887.472 | 2.087.276 | 18.221.879 | 29.597.811 | 35.196.187 | 59.716.252 |
| Inventories | - | - | - | - | 221.815 | 546.811 | 5.644.206 | 6.150.837 | 5.474.379 | 8.726.798 |
| Receivables | - | - | - | - | 665.658 | 1.540.465 | 12.577.673 | 23.446.974 | 29.721.809 | 50.687.379 |
| Cash | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 302.074 |
| Shareholders Funds | - | - | - | - | 147.501 | 248.672 | 514.358 | 1.458.788 | 3.033.852 | 4.214.472 |
| Social Capital | - | - | - | - | 52.683 | 51.684 | 50.538 | 50.695 | 50.541 | 70.848 |
| Debts | - | - | - | - | 744.739 | 1.853.489 | 17.731.525 | 28.163.690 | 32.174.688 | 55.510.274 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Addenda Pharmaceuticals S.r.l.